Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone)
- PMID: 8241694
- DOI: 10.1007/BF00226851
Perspectives on therapy of cardiovascular diseases with coenzyme Q10 (ubiquinone)
Abstract
A defective myocardial energy supply--due to lack of substrates and/or essential cofactors and a poor utilization efficiency of oxygen--may be a common final pathway in the progression of myocardial diseases of various etiologies. The vitamin-like essential substance coenzyme Q10, or ubiquinone, is a natural antioxidant and has a key role in oxidative phosphorylation. A biochemical rationale for using coenzyme Q10 as a therapy in heart disease was established years ago by Folkers and associates; however, this has been further strengthened by investigations of viable myocardial tissue from the author's series of 45 patients with various cardiomyopathies. Myocardial tissue levels of coenzyme Q10 determined by high-performance lipid chromatography were found to be significantly lower in patients with more advanced heart failure compared with those in the milder stages of heart failure. Furthermore, the myocardial tissue coenzyme Q10 deficiency might be restored significantly by oral supplementation in selected cases. In the author's open clinical protocol study with coenzyme Q10 therapy (100 mg daily) nearly two-thirds of patients revealed clinical improvement, most pronounced in those with dilated cardiomyopathy. Double-blind placebo-controlled trials have definitely confirmed that coenzyme Q10 has a place as adjunctive treatment in heart failure with beneficial effects on the clinical outcome, the patients' physical activity, and their quality of life. The positive results have been above and beyond the clinical status obtained from treatment with traditional principles--including angiotensin-converting enzyme inhibitors.
Similar articles
-
[Physiological aspects of ubiquinone supplementation in cardiovascular pathology].Fiziol Zh (1994). 2006;52(5):80-91. Fiziol Zh (1994). 2006. PMID: 17176844 Review. Ukrainian.
-
Coenzyme Q10 in health and disease.Eur J Clin Nutr. 1999 Oct;53(10):764-70. doi: 10.1038/sj.ejcn.1600880. Eur J Clin Nutr. 1999. PMID: 10556981 Review.
-
Coenzyme Q in cardiovascular disease.J Assoc Physicians India. 1998 Mar;46(3):299-306. J Assoc Physicians India. 1998. PMID: 11273351 Review.
-
Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio"--a multinational trial.Biofactors. 2003;18(1-4):79-89. doi: 10.1002/biof.5520180210. Biofactors. 2003. PMID: 14695923 Review.
-
Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure.Int J Tissue React. 1990;12(3):155-62. Int J Tissue React. 1990. PMID: 2276893 Review.
Cited by
-
Dramatic improvement in mitochondrial cardiomyopathy following treatment with idebenone.J Inherit Metab Dis. 2001 Feb;24(1):28-34. doi: 10.1023/a:1005642302316. J Inherit Metab Dis. 2001. PMID: 11286379
-
Coenzyme Q10 for the treatment of heart failure: a review of the literature.Open Heart. 2015 Oct 19;2(1):e000326. doi: 10.1136/openhrt-2015-000326. eCollection 2015. Open Heart. 2015. PMID: 26512330 Free PMC article. Review.
-
Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction.Pharm Res. 2007 Nov;24(11):2131-7. doi: 10.1007/s11095-007-9334-0. Epub 2007 Jul 27. Pharm Res. 2007. PMID: 17657597
-
Preparation and characterization of novel coenzyme Q10 nanoparticles engineered from microemulsion precursors.AAPS PharmSciTech. 2003;4(3):E32. doi: 10.1208/pt040332. AAPS PharmSciTech. 2003. PMID: 14621964 Free PMC article.
-
Coenzyme Q10 for heart failure.Cochrane Database Syst Rev. 2021 Feb 3;(2)(2):CD008684. doi: 10.1002/14651858.CD008684.pub3. Cochrane Database Syst Rev. 2021. PMID: 35608922 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources